A $2 million drug is about to hit the market

Wall Street Journal

8 May 2019 -Insurers, drug makers grapple with new payment models for gene therapies that can cure diseases in one treatment.

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

Novartis AG has yet to set a price for the gene therapy called Zolgensma, but executives say the drug’s potential to cure spinal muscular atrophy, an inherited disease that typically kills babies before they turn two, justifies a seven-figure price.

Read Wall Street Journal article (subscription required)

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Pricing , Gene therapy